Novavax Investor Relations https://ir.novavax.com/ Novavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season https://novavax.investorroom.com/2026-08-28-Novavaxs-Partnership-Strategy-Continues-to-Deliver-with-XFG-adapted-Nuvaxovid-TM-Approvals-in-the-U-S-,-EU-and-Japan-for-2026-2027-Vaccination-Season <p>COVID-19 remains a public health challenge, particularly among older adults and high-risk populations1 Novavax's partners are ready to bring its protein-based, non-mRNA vaccine with a favorable...</p> 08/28/2026 https://novavax.investorroom.com/2026-08-28-Novavaxs-Partnership-Strategy-Continues-to-Deliver-with-XFG-adapted-Nuvaxovid-TM-Approvals-in-the-U-S-,-EU-and-Japan-for-2026-2027-Vaccination-Season Nuvaxovid™ COVID-19 Vaccine Showed Better Tolerability than mNEXSPIKE in Head-to-head Sanofi-led Phase 4 Study https://novavax.investorroom.com/press-releases?item=610 <p>Sanofi presented positive results from COMPARE, the first head-to-head, double-blind, randomized Phase 4 study powered to directly compare the tolerability profiles of Novavax&rsquo;s protein-based non-mRNA COVID-19 vaccine Nuvaxovid&trade; and mNEXSPIKE, Moderna&#39;s latest mRNA COVID-19 vaccine. The study showed that Nuvaxovid demonstrated statistically significant lower systemic reactogenicity (the expected side effects that might occur following vaccination) compared to mNEXSPIKE across all pre-specified endpoints.</p> 04/18/2026 https://novavax.investorroom.com/press-releases?item=610 Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment https://novavax.investorroom.com/2025-11-04-Novavax-Completes-U-S-Marketing-Authorization-Transfer-to-Sanofi-for-Nuvaxovid-TM-,-Triggering-a-25-Million-Milestone-Payment <p>Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid™ to Sanofi in line with its CLA and its corporate strategy,...</p> 11/04/2025 https://novavax.investorroom.com/2025-11-04-Novavax-Completes-U-S-Marketing-Authorization-Transfer-to-Sanofi-for-Nuvaxovid-TM-,-Triggering-a-25-Million-Milestone-Payment Novavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment https://novavax.investorroom.com/2025-10-07-Novavax-Continues-to-Deliver-on-Sanofi-Partnership,-Completing-Nuvaxovid-R-EU-Marketing-Authorization-Transfer-and-Triggering-25-Million-Milestone-Payment <p>Novavax, Inc. (Nasdaq: NVAX) has completed the transfer of the marketing authorization for its COVID-19 vaccine, Nuvaxovid® to Sanofi, in the European Union (EU) enabling Sanofi to take full...</p> 10/07/2025 https://novavax.investorroom.com/2025-10-07-Novavax-Continues-to-Deliver-on-Sanofi-Partnership,-Completing-Nuvaxovid-R-EU-Marketing-Authorization-Transfer-and-Triggering-25-Million-Milestone-Payment Sanofi and Novavax Statement on Nuvaxovid™ COVID-19 vaccine for ACIP  https://novavax.investorroom.com/Sanofi-and-Novavax-Statement-on-Nuvaxovid-TM-COVID-19-vaccine-for-ACIP <p>Introductory Remarks for Nuvaxovid at September 2025 Advisory Committee on Immunization Practices (ACIP) Meeting</p> 09/19/2025 https://novavax.investorroom.com/Sanofi-and-Novavax-Statement-on-Nuvaxovid-TM-COVID-19-vaccine-for-ACIP